Which has preferable earnings & valuation, MRNA or JNJ?

Johnson & Johnson has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 13.93 -$2.82B -$8.15 N/A Johnson & Johnson $94.19B 6.57 $26.80B $8.65 29.73

Is MRNA or JNJ more profitable?

Johnson & Johnson has a net margin of 21.83% compared to Moderna's net margin of -143.55%. Johnson & Johnson's return on equity of 32.60% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Johnson & Johnson 21.83% 32.60% 13.29%

Does the media refer more to MRNA or JNJ?

In the previous week, Johnson & Johnson had 56 more articles in the media than Moderna. MarketBeat recorded 84 mentions for Johnson & Johnson and 28 mentions for Moderna. Johnson & Johnson's average media sentiment score of 1.19 beat Moderna's score of 0.74 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 12 Very Positive mention(s) 7 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Johnson & Johnson 58 Very Positive mention(s) 12 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Which has preferable valuation & earnings, NVAX or JNJ?

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.37 $440.30M -$0.58 N/A Johnson & Johnson $94.19B 6.57 $26.80B $8.65 29.73

Is NVAX or JNJ more profitable?

Johnson & Johnson has a net margin of 21.83% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.60% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Johnson & Johnson 21.83% 32.60% 13.29%

Does the media refer more to NVAX or JNJ?

In the previous week, Johnson & Johnson had 62 more articles in the media than Novavax. MarketBeat recorded 84 mentions for Johnson & Johnson and 22 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.19 beat Novavax's score of 0.71 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Johnson & Johnson 58 Very Positive mention(s) 12 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Which has preferable earnings & valuation, JNJ or ABBV?

Johnson & Johnson has higher revenue and earnings than AbbVie. Johnson & Johnson is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $94.19B 6.57 $26.80B $8.65 29.73 AbbVie $61.16B 7.16 $4.23B $2.03 122.17

Is JNJ or ABBV more profitable?

Johnson & Johnson has a net margin of 21.83% compared to AbbVie's net margin of 5.79%. Johnson & Johnson's return on equity of 32.60% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Johnson & Johnson 21.83% 32.60% 13.29% AbbVie 5.79% -576.45% 13.39%

Does the media favor JNJ or ABBV?

In the previous week, Johnson & Johnson had 44 more articles in the media than AbbVie. MarketBeat recorded 84 mentions for Johnson & Johnson and 40 mentions for AbbVie. Johnson & Johnson's average media sentiment score of 1.19 beat AbbVie's score of 0.87 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 58 Very Positive mention(s) 12 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive AbbVie 18 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, JNJ or AZN?

Johnson & Johnson has higher revenue and earnings than Astrazeneca. Astrazeneca is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $94.19B 6.57 $26.80B $8.65 29.73 Astrazeneca $58.74B 4.54 $10.23B $6.66 25.80

Does the media refer more to JNJ or AZN?

In the previous week, Johnson & Johnson had 53 more articles in the media than Astrazeneca. MarketBeat recorded 84 mentions for Johnson & Johnson and 31 mentions for Astrazeneca. Johnson & Johnson's average media sentiment score of 1.19 beat Astrazeneca's score of 0.24 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 58 Very Positive mention(s) 12 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Astrazeneca 14 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 7 Negative mention(s) 3 Very Negative mention(s) Neutral

Does the media favor BRK.B or JNJ?

In the previous week, Johnson & Johnson had 75 more articles in the media than Berkshire Hathaway. MarketBeat recorded 84 mentions for Johnson & Johnson and 9 mentions for Berkshire Hathaway. Johnson & Johnson's average media sentiment score of 1.19 beat Berkshire Hathaway's score of 0.38 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Berkshire Hathaway 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Johnson & Johnson 58 Very Positive mention(s) 12 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Johnson & Johnson (JNJ) Competitors

$257.17 -1.93 (-0.74%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$256.88 -0.29 (-0.11%)

As of 07/10/2026 07:59 PM Eastern

Compare

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

Should you buy Johnson & Johnson stock or one of its competitors? MarketBeat compares Johnson & Johnson with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Johnson & Johnson include Moderna (MRNA), Novavax (NVAX), AbbVie (ABBV), Astrazeneca (AZN), and Berkshire Hathaway (BRK.B).

How does Johnson & Johnson compare to Moderna?

Moderna (NASDAQ:MRNA) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Moderna presently has a consensus target price of $38.27, suggesting a potential downside of 43.95%. Johnson & Johnson has a consensus target price of $258.13, suggesting a potential upside of 0.37%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

Johnson & Johnson has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	13.93	-$2.82B	-$8.15	N/A
Johnson & Johnson	$94.19B	6.57	$26.80B	$8.65	29.73

75.3% of Moderna shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Johnson & Johnson had 56 more articles in the media than Moderna. MarketBeat recorded 84 mentions for Johnson & Johnson and 28 mentions for Moderna. Johnson & Johnson's average media sentiment score of 1.19 beat Moderna's score of 0.74 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	12 Very Positive mention(s)	7 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	58 Very Positive mention(s)	12 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Johnson & Johnson has a net margin of 21.83% compared to Moderna's net margin of -143.55%. Johnson & Johnson's return on equity of 32.60% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Johnson & Johnson	21.83%	32.60%	13.29%

Moderna has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Summary

Johnson & Johnson beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Johnson & Johnson compare to Novavax?

Novavax (NASDAQ:NVAX) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Johnson & Johnson has a net margin of 21.83% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.60% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Johnson & Johnson	21.83%	32.60%	13.29%

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.37	$440.30M	-$0.58	N/A
Johnson & Johnson	$94.19B	6.57	$26.80B	$8.65	29.73

Novavax has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

In the previous week, Johnson & Johnson had 62 more articles in the media than Novavax. MarketBeat recorded 84 mentions for Johnson & Johnson and 22 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.19 beat Novavax's score of 0.71 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Johnson & Johnson	58 Very Positive mention(s)	12 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

53.0% of Novavax shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Novavax presently has a consensus price target of $13.00, indicating a potential upside of 39.34%. Johnson & Johnson has a consensus price target of $258.13, indicating a potential upside of 0.37%. Given Novavax's higher probable upside, analysts clearly believe Novavax is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

Summary

Johnson & Johnson beats Novavax on 13 of the 17 factors compared between the two stocks.

How does Johnson & Johnson compare to AbbVie?

Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Johnson & Johnson has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

Johnson & Johnson has higher revenue and earnings than AbbVie. Johnson & Johnson is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.57	$26.80B	$8.65	29.73
AbbVie	$61.16B	7.16	$4.23B	$2.03	122.17

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Johnson & Johnson had 44 more articles in the media than AbbVie. MarketBeat recorded 84 mentions for Johnson & Johnson and 40 mentions for AbbVie. Johnson & Johnson's average media sentiment score of 1.19 beat AbbVie's score of 0.87 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	58 Very Positive mention(s)	12 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
AbbVie	18 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Johnson & Johnson has a net margin of 21.83% compared to AbbVie's net margin of 5.79%. Johnson & Johnson's return on equity of 32.60% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
AbbVie	5.79%	-576.45%	13.39%

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.1%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Johnson & Johnson pays out 62.0% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has increased its dividend for 64 consecutive years and AbbVie has increased its dividend for 53 consecutive years.

Johnson & Johnson currently has a consensus target price of $258.13, indicating a potential upside of 0.37%. AbbVie has a consensus target price of $262.81, indicating a potential upside of 5.97%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84

Summary

Johnson & Johnson beats AbbVie on 11 of the 20 factors compared between the two stocks.

How does Johnson & Johnson compare to Astrazeneca?

Johnson & Johnson (NYSE:JNJ) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.1%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.5%. Johnson & Johnson pays out 62.0% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 64 consecutive years.

Johnson & Johnson currently has a consensus target price of $258.13, indicating a potential upside of 0.37%. Astrazeneca has a consensus target price of $211.00, indicating a potential upside of 22.78%. Given Astrazeneca's stronger consensus rating and higher possible upside, analysts plainly believe Astrazeneca is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

Johnson & Johnson has higher revenue and earnings than Astrazeneca. Astrazeneca is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.57	$26.80B	$8.65	29.73
Astrazeneca	$58.74B	4.54	$10.23B	$6.66	25.80

In the previous week, Johnson & Johnson had 53 more articles in the media than Astrazeneca. MarketBeat recorded 84 mentions for Johnson & Johnson and 31 mentions for Astrazeneca. Johnson & Johnson's average media sentiment score of 1.19 beat Astrazeneca's score of 0.24 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	58 Very Positive mention(s)	12 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Astrazeneca	14 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	7 Negative mention(s)	3 Very Negative mention(s)	Neutral

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Johnson & Johnson has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Johnson & Johnson has a net margin of 21.83% compared to Astrazeneca's net margin of 17.19%. Johnson & Johnson's return on equity of 32.60% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
Astrazeneca	17.19%	30.86%	12.68%

Summary

Johnson & Johnson beats Astrazeneca on 15 of the 18 factors compared between the two stocks.

How does Johnson & Johnson compare to Berkshire Hathaway?

Berkshire Hathaway (NYSE:BRK.B) and Johnson & Johnson (NYSE:JNJ) are related large-cap companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Johnson & Johnson has a net margin of 21.83% compared to Berkshire Hathaway's net margin of 19.31%. Johnson & Johnson's return on equity of 32.60% beat Berkshire Hathaway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Berkshire Hathaway	19.31%	6.55%	3.80%
Johnson & Johnson	21.83%	32.60%	13.29%

Berkshire Hathaway currently has a consensus price target of $524.50, suggesting a potential upside of 6.22%. Johnson & Johnson has a consensus price target of $258.13, suggesting a potential upside of 0.37%. Given Berkshire Hathaway's higher probable upside, equities analysts clearly believe Berkshire Hathaway is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Berkshire Hathaway	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

In the previous week, Johnson & Johnson had 75 more articles in the media than Berkshire Hathaway. MarketBeat recorded 84 mentions for Johnson & Johnson and 9 mentions for Berkshire Hathaway. Johnson & Johnson's average media sentiment score of 1.19 beat Berkshire Hathaway's score of 0.38 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Berkshire Hathaway	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Johnson & Johnson	58 Very Positive mention(s)	12 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Berkshire Hathaway has higher revenue and earnings than Johnson & Johnson. Berkshire Hathaway is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Berkshire Hathaway	$371.44B	2.87	$66.97B	$33.59	14.70
Johnson & Johnson	$94.19B	6.57	$26.80B	$8.65	29.73

39.3% of Berkshire Hathaway shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 6.1% of Berkshire Hathaway shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Berkshire Hathaway has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Summary

Johnson & Johnson beats Berkshire Hathaway on 10 of the 16 factors compared between the two stocks.

Get Johnson & Johnson News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JNJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JNJ vs. The Competition

Export

Metric	Johnson & Johnson	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$623.71B	$333.45B	$7.12B	$23.43B
Dividend Yield	2.07%	2.68%	2.68%	4.04%
P/E Ratio	29.73	29.70	27.22	31.27
Price / Sales	6.57	5.41	590.16	20.39
Price / Cash	18.35	14.20	49.34	25.05
Price / Book	7.60	8.37	10.90	4.77
Net Income	$26.80B	$11.61B	$3.57B	$1.07B
7 Day Performance	-2.04%	-2.39%	-0.25%	-0.50%
1 Month Performance	7.79%	7.32%	5.77%	2.09%
1 Year Performance	63.94%	25.70%	28.14%	16.03%

Johnson & Johnson Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JNJ Johnson & Johnson	4.4073 of 5 stars	$257.17 -0.7%	$258.13 +0.4%	+63.1%	$623.71B	$94.19B	29.73	138,200	Trending News Upcoming Earnings Analyst Forecast
MRNA Moderna	2.1873 of 5 stars	$79.46 -2.9%	$37.87 -52.3%	+99.2%	$31.48B	$1.94B	N/A	4,700	Trending News Analyst Forecast Options Volume
NVAX Novavax	2.5403 of 5 stars	$9.30 -0.6%	$13.00 +39.9%	+31.4%	$1.53B	$1.12B	N/A	1,990	Trending News Options Volume Analyst Revision
ABBV AbbVie	4.7491 of 5 stars	$255.95 +0.5%	$256.67 +0.3%	+27.2%	$452.68B	$61.16B	126.21	57,000	Trending News Analyst Forecast
AZN Astrazeneca	4.5767 of 5 stars	$192.16 +1.1%	$205.33 +6.9%	+19.7%	$298.00B	$58.74B	28.85	96,100	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:JNJ) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Competitors

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

How does Johnson & Johnson compare to Moderna?

Summary

How does Johnson & Johnson compare to Novavax?

Summary

How does Johnson & Johnson compare to AbbVie?

Summary

How does Johnson & Johnson compare to Astrazeneca?

Summary

How does Johnson & Johnson compare to Berkshire Hathaway?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ vs. The Competition

Johnson & Johnson Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Johnson & Johnson (JNJ) Competitors

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

How does Johnson & Johnson compare to Moderna?

Do analysts recommend MRNA or JNJ?

Which has preferable earnings & valuation, MRNA or JNJ?

Do institutionals and insiders hold more shares of MRNA or JNJ?

Does the media refer more to MRNA or JNJ?

Is MRNA or JNJ more profitable?

Which has more risk & volatility, MRNA or JNJ?

Summary

How does Johnson & Johnson compare to Novavax?

Is NVAX or JNJ more profitable?

Which has preferable valuation & earnings, NVAX or JNJ?

Which has more volatility and risk, NVAX or JNJ?

Does the media refer more to NVAX or JNJ?

Do institutionals & insiders believe in NVAX or JNJ?

Do analysts recommend NVAX or JNJ?

Summary

How does Johnson & Johnson compare to AbbVie?

Which has more risk and volatility, JNJ or ABBV?

Which has preferable earnings & valuation, JNJ or ABBV?

Do insiders and institutionals have more ownership in JNJ or ABBV?

Does the media favor JNJ or ABBV?

Is JNJ or ABBV more profitable?

Is JNJ or ABBV a better dividend stock?

Do analysts prefer JNJ or ABBV?

Summary

How does Johnson & Johnson compare to Astrazeneca?

Is JNJ or AZN a better dividend stock?

Do analysts recommend JNJ or AZN?

Which has stronger earnings & valuation, JNJ or AZN?

Does the media refer more to JNJ or AZN?

Do institutionals and insiders believe in JNJ or AZN?

Which has more risk & volatility, JNJ or AZN?

Is JNJ or AZN more profitable?

Summary

How does Johnson & Johnson compare to Berkshire Hathaway?

Is BRK.B or JNJ more profitable?

Do analysts rate BRK.B or JNJ?

Does the media favor BRK.B or JNJ?

Which has higher earnings and valuation, BRK.B or JNJ?

Do institutionals & insiders believe in BRK.B or JNJ?

Which has more volatility & risk, BRK.B or JNJ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ vs. The Competition

Johnson & Johnson Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools